Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay.

Journal for Immunotherapy of Cancer
Diego A LemaTiciana Leal

Abstract

Emerging evidence has shown a role for tumor antigen-specific regulation in cancer. Identifying individuals with pre-existing regulatory responses may be key to understand those who are more likely to respond to Programmed Death-1 (PD-1) or PD-1 Ligand 1 (PD-L1) checkpoint blockade. We hypothesized that a functional assay could identify the role of PD-1/PD-L1 interactions on tumor-specific immune cells in the peripheral blood in patients with advanced non-small-cell lung cancer (NSCLC). We performed the trans vivo delayed-type hypersensitivity assay to identify the role of PD-1/PD-L1-mediated tumor-specific immune regulation in ten patients with advanced NSCLC. The majority of patients had PD-1-mediated anergic immune responses towards their tumor antigens. Eight out of nine of these patients did not respond to their own tumor antigens but responded in the presence of anti-PD-1 antibody ('PD-1 anergy' phenotype). A minority (3/9) also had 'active' PD-1-mediated immune suppressive regulatory responses. Our results suggest that PD-1-anergy is a common feature of NSCLC immune responses, whereas PD-1-mediated immune suppression is present only in a minority of patients. The latter was associated with poor clinical outcomes in our s...Continue Reading

References

Nov 4, 2005·Cancer Research·Friedrich H Schmitz-WinnenthalPhilipp Beckhove
Dec 19, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·W J Burlingham, E Jankowska-Gan
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Richard A DerksWilliam J Burlingham
Sep 17, 2009·General Thoracic and Cardiovascular Surgery·Kosei YasumotoMitsuhiro Takenoyama
Nov 16, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brian M OlsonDouglas G McNeel
May 15, 2013·Journal of Visualized Experiments : JoVE·Ewa Jankowska-GanWilliam J Burlingham
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Mar 18, 2017·The Journal of Experimental Medicine·Vikram R JunejaArlene H Sharpe
Apr 28, 2017·Proceedings of the National Academy of Sciences of the United States of America·Alice O KamphorstSuresh S Ramalingam
Apr 17, 2018·The New England Journal of Medicine·Matthew D HellmannLuis Paz-Ares
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Jul 5, 2018·Anticancer Research·Maria BassanelliAnna Ceribelli
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Oct 4, 2018·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators
Oct 10, 2018·Proceedings of the National Academy of Sciences of the United States of America·Marcin KowanetzPriti S Hegde
Dec 18, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OttJared K Lunceford

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
blood draw

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.